185 related articles for article (PubMed ID: 19915358)
1. [Clinical progress in chronic myelogenous leukemia].
Matsunaga T
Rinsho Ketsueki; 2009 Oct; 50(10):1489-99. PubMed ID: 19915358
[No Abstract] [Full Text] [Related]
2. [Chronic myeloid leukemia: up-to-date management].
Nakayama K; Inokuchi K
Rinsho Ketsueki; 2014 Jan; 55(1):42-55. PubMed ID: 24492036
[No Abstract] [Full Text] [Related]
3. [Management of chronic myeloid leukemia].
Kubuki Y
Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
[No Abstract] [Full Text] [Related]
4. [Treatment of chronic myeloid leukemia in chronic phase].
Matsumura I
Rinsho Ketsueki; 2014 Oct; 55(10):1853-9. PubMed ID: 25297749
[No Abstract] [Full Text] [Related]
5. [Chronic myeloid leukemia 2008].
Cervantes F
Med Clin (Barc); 2008 Nov; 131(17):658-9. PubMed ID: 19087793
[No Abstract] [Full Text] [Related]
6. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
7. [Management of advanced stage chronic myeloid leukemia].
Takahashi N
Rinsho Ketsueki; 2014 Oct; 55(10):1860-9. PubMed ID: 25297750
[No Abstract] [Full Text] [Related]
8. [TKI therapy for CML].
Ohnishi K
Rinsho Ketsueki; 2011 Jul; 52(7):452-9. PubMed ID: 21821976
[No Abstract] [Full Text] [Related]
9. Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment.
Bumbea H; Vladareanu AM; Voican I; Cisleanu D; Barsan L; Onisai M
J Med Life; 2010; 3(2):162-6. PubMed ID: 20968202
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Miura M; Takahashi N
Rinsho Ketsueki; 2013 Oct; 54(10):1720-9. PubMed ID: 24064822
[No Abstract] [Full Text] [Related]
11. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukemia: advances in diagnosis and management.
Noronha S; Sawyer S
JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
[No Abstract] [Full Text] [Related]
13. Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.
Gambacorti-Passerini C; Piazza R
Am J Hematol; 2011 Jul; 86(7):531-2. PubMed ID: 21674581
[No Abstract] [Full Text] [Related]
14. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
Hussein K; Bock O; Seegers A; Flasshove M; Henneke F; Buesche G; Kreipe HH
Blood; 2007 May; 109(9):4106-7. PubMed ID: 17449802
[No Abstract] [Full Text] [Related]
15. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
[TBL] [Abstract][Full Text] [Related]
16. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G
Blood; 2009 Sep; 114(10):2168-71. PubMed ID: 19589924
[TBL] [Abstract][Full Text] [Related]
17. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
Goulden S; Sutcliffe F; Stevens A
Lancet Oncol; 2012 Feb; 13(2):127-8. PubMed ID: 22403810
[No Abstract] [Full Text] [Related]
18. Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
Hayette S; Chabane K; Tchirkov A; Berger MG; Nicolini FE; Tournilhac O
Haematologica; 2009 Sep; 94(9):1324-6. PubMed ID: 19734429
[No Abstract] [Full Text] [Related]
19. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
[TBL] [Abstract][Full Text] [Related]
20. Oral BMS-354825 rescues Gleevec-resistant CML.
Cancer Biol Ther; 2004 Aug; 3(8):700. PubMed ID: 15751154
[No Abstract] [Full Text] [Related]
[Next] [New Search]
